Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644494
Distensibility Index of Inferior Vena Cava in Assessing Fluid Responsiveness: The Impact of Spontaneous Respiratory EffortJingyuan,XuCompleted
NCT07644494Completed
—
Distensibility Index of Inferior Vena Cava in Assessing Fluid Responsiveness: Th...Jingyuan,Xu
NCT07645508
Comparison of Conventional, Patient-Specific, and Augmented Reality Navigation in Reverse Total Shoulder ArthroplastyKrankenhaus Barmherzige Schwestern LinzActive Not Recruiting
NCT07645508Active Not Recruiting
—
Comparison of Conventional, Patient-Specific, and Augmented Reality Navigation i...Krankenhaus Barmherzige S...
NCT07644975
Electrolytic Surface Decontamination in the Surgical Treatment of Peri-implantitis: A Randomized Clinical TrialIstanbul UniversityNot Yet RecruitingNot Applicable
NCT07644975Not Yet Recruiting
Not Applicable
Electrolytic Surface Decontamination in the Surgical Treatment of Peri-implantit...Istanbul University
NCT07645365
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialysis UnitAntalya Health Sciences UniversityCompleted
NCT07645365Completed
—
Hemodialysis Catheter Complications in the Emergency Department Versus Hemodialy...Antalya Health Sciences U...
NCT07646236
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan Hospital-China Medical UniversityCompletedNot Applicable
NCT07646236Completed
Not Applicable
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan H...
NCT07645742
Pilot Study of Intermittent Fasting With Immune Checkpoint InhibitorsWest Virginia UniversityNot Yet RecruitingNot Applicable
NCT07645742Not Yet Recruiting
Not Applicable
Pilot Study of Intermittent Fasting With Immune Checkpoint InhibitorsWest Virginia University
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07645131
Development of a Mobile Health Intervention to Support Functioning of Veterans With Substance Use DisordersVA Office of Research and DevelopmentNot Yet RecruitingNot Applicable
NCT07645131Not Yet Recruiting
Not Applicable
Development of a Mobile Health Intervention to Support Functioning of Veterans W...VA Office of Research and...
NCT07646587
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants With Moderate - Severe COPDWindward BioRecruitingPhase 2
NCT07646587Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, PK and PD of WIN378 in Participants...Windward Bio
NCT07645105
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or ObesityMedical University of SilesiaCompleted
NCT07645105Completed
—
Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obes...Medical University of Sil...
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07645053
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal SurgeryHospital Edmundo VasconcelosCompletedPhase 1
NCT07645053Completed
Phase 1
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal...Hospital Edmundo Vasconce...
NCT07646366
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee OsteoarthritisRiphah International UniversityNot Yet RecruitingNot Applicable
NCT07646366Not Yet Recruiting
Not Applicable
Effects of the Egoscue Exercises With and Without Mwm Among Patients With Knee O...Riphah International Univ...
NCT07644312
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPGNationwide Children's HospitalNot Yet RecruitingPhase 2
NCT07644312Not Yet Recruiting
Phase 2
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG...Nationwide Children's Hos...
NCT07643935
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timing of ResponseCentral Hospital, Nancy, FranceNot Yet Recruiting
NCT07643935Not Yet Recruiting
—
Prognostic Value of 177Lutetium-PSMA Single Photon Emission Tomography and Timin...Central Hospital, Nancy,...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07645495
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645495Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Therapy in Chronic Ulcers.Beni-Suef University
NCT07644351
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia PatientsNovartis PharmaceuticalsCompleted
NCT07644351Completed
—
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lym...Novartis Pharmaceuticals
Result Breakdown
Not yet recruiting10 (50%)
Completed6 (30%)
Recruiting3 (15%)
Active, not recruiting1 (5%)
Not Specified7 (35%)
not_applicable7 (35%)
Phase 13 (15%)
Phase 23 (15%)